Autoimmune diseases, immune modulation, inflammation, and self-tolerance
221 articoli
A runaway immune response — not the pathogen itself — drives citrus greening disease, echoing autoimmune mechanisms seen in human illness.
A novel biologic targeting IL-33 shows promising advances in COPD treatment, potentially reshaping how chronic lung disease is managed.
A murine arthritis study finds rapamycin suppresses neuropeptide Y, linking cellular senescence to joint inflammation via SASP cytokines.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
JAMA publishes a timely review of IgA nephropathy, the leading cause of primary glomerulonephritis worldwide, amid a wave of new therapies.
Nephrologists from Canada and Ireland address clinical questions on IgA nephropathy, one of the most common causes of kidney failure worldwide.
Un'analisi meccanicistica approfondita sugli interventi all'avanguardia contro l'inflammaging — dalla farmacologia senolitica e il targeting di precisione delle citochine alle strategie di riprogrammazione parziale che mirano a ripristinare l'omeostasi immunitaria giovanile.
Vai oltre le basi dell'inflammaging per capire come l'invecchiamento ridisegna le popolazioni di cellule immunitarie, innesca il SASP e blocca l'organismo in uno stato di infiammazione cronica di basso grado a livello molecolare.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Early influenza infections leave a lasting immunological imprint that determines how your immune system responds to entirely different flu strains later in life.
Senescent T cells fuel psoriasis, eczema, and rosacea through toxic secretions. New therapies may finally break the cycle.
A new in vitro study shows Thymosin α1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
